Small Molecule Activators of Trk Receptors for Neuroprotection
Author Information
Author(s): Nicholas JG Webster, Michael C Pirrung
Primary Institution: Veterans Medical Research Foundation and VA San Diego Healthcare System, San Diego, California, USA
Hypothesis
Can small molecule activators of Trk receptors provide neuroprotection in neurodegenerative diseases?
Conclusion
The study suggests that small molecule activators of Trk receptors may enhance neurotrophin signaling and provide neuroprotection in conditions like Alzheimer's disease.
Supporting Evidence
- Neurotrophins are critical for the survival of many neuronal populations.
- Cholinergic neurons in the basal forebrain are lost in Alzheimer's disease.
- Small molecules that activate Trk receptors may overcome the limitations of neurotrophin therapy.
Takeaway
This study looks at how certain small molecules can help protect brain cells from dying, which is important for diseases like Alzheimer's.
Methodology
The review discusses various pharmacological strategies and evidence supporting the role of neurotrophins in preventing neurodegeneration.
Limitations
The pharmacokinetic behavior and bioavailability of neurotrophins limit their therapeutic use.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website